BrYet US, Inc. (“BrYet”) — a biotechnology innovator focused on developing curative therapies for advanced cancers — ...

HOUSTON, TX / ACCESS Newswire / March 4, 2026 / BrYet US, Inc. ("BrYet") - a biotechnology innovator focused on ...

A new study by researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain ...

The accelerated approval for patients with HER2 (ERBB2)-mutated disease follows an approval last August for use after prior ...

Gut microbiota may shape liver metastasis in small cell lung cancer and influence treatment response. Read more.

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is ...

Real-world data show that Enhertu (fam-trastuzumab deruxtecan-nxki) was tolerated as well in the community setting, where ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...

Scientists have developed an AI system that analyzes complex gene-expression signatures to estimate the likelihood that a ...

The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.

A new study from researchers at Wake Forest University School of Medicine has identified a promising strategy to treat brain metastases, one of the most challenging and deadly complications of lung ...

Cancer spreads (metastasizes) when tumor cells shed from a primary solid tumor (for example, in the breast) and embed in ...